Biomarkers for Progressive Supranuclear Palsy

Migration, Crosslink

📖

Biomarkers for Progressive Supranuclear Palsy

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-progressive-supranuclear

📖 Wiki Page

biomarker2622 wordssynced 2026-04-02

Introduction

Biomarkers For Progressive Supranuclear Palsy is an important topic in neurodegenerative disease research. This page provides comprehensive information about its relevance, mechanisms, and implications for the field.

Overview

PSP biomarkers can be categorized based on the pathological process they reflect:

Tau biomarkers: Direct measures of tau pathology
Neurodegeneration markers: Indicators of neuronal and axonal damage
Neuroinflammation markers: Glial activation and immune responses
Genetic markers: Risk factors and diagnostic genetic tests

The distinction between PSP and other tauopathies (CBD, corticobasal syndrome) remains challenging but is improving with biomarker advances.

Biomarker Detection Pathway

flowchart TD A["Tau Pathology in Brain"] --> B["Neuronal Injury"] B --> C["CSF Biomarkers"] B --> D["Blood Biomarkers"] C --> C1["NfL - Neurofilament Light"] C --> C2["t-Tau - Total Tau"] C --> C3["p-Tau - Phosphorylated Tau"] C --> C4["GFAP - Glial Marker"] D --> D1["Plasma NfL"] D --> D2["Plasma p-Tau181"] D --> D3["Plasma p-Tau217"] D --> D4["Plasma GFAP"] C1 --> E["Disease Progression"] C2 --> E C3 --> F["AD Co-Pathology"] C4 --> G["Neuroinflammation"] E --> H["Clinical Monitoring"] F --> I["Treatment Decisions"] G --> H style A fill:#1a0a1f,stroke:#333,color:#e0e0e0 style E fill:#9f9,stroke:#333,color:#0d0d1a style H fill:#9f9,stroke:#333,color:#0d0d1a

Biomarker Interpretation Framework

...

Introduction

Biomarkers For Progressive Supranuclear Palsy is an important topic in neurodegenerative disease research. This page provides comprehensive information about its relevance, mechanisms, and implications for the field.

Overview

PSP biomarkers can be categorized based on the pathological process they reflect:

Tau biomarkers: Direct measures of tau pathology
Neurodegeneration markers: Indicators of neuronal and axonal damage
Neuroinflammation markers: Glial activation and immune responses
Genetic markers: Risk factors and diagnostic genetic tests

The distinction between PSP and other tauopathies (CBD, corticobasal syndrome) remains challenging but is improving with biomarker advances.

Biomarker Detection Pathway

Mermaid diagram (expand to render)

Biomarker Interpretation Framework

Mermaid diagram (expand to render)

Cerebrospinal Fluid Biomarkers

Tau Biomarkers

Total Tau (t-tau):

Moderately elevated in PSP compared to controls
Higher levels correlate with disease severity
Less specific than p-tau for tau pathology

Phosphorylated Tau (p-tau181, p-tau217biomarkers/p-tau217), p-tau231):

p-tau181: Elevated in PSP vs. PD, but lower than AD
p-tau217: Shows promise for distinguishing PSP from CBD
p-tau231: May correlate with disease progression
Higher p-tau/t-tau ratio in PSP vs. AD

Tau Oligomers:

Emerging biomarker for toxic tau aggregates
Correlates with clinical severity
Under validation for clinical use

Neurodegeneration Markers

Neurofilament Light Chain (NfL):

Significantly elevated in PSP vs. controls
Higher levels than in PD but lower than in ALS
Predicts disease progression rate
Useful for tracking treatment response
FDA-approved for ALS, applicable to PSP

Neurofilament Heavy Chain (pNfH):

Axonal damage marker
Elevated in PSP CSF
Correlates with disease severity

Neuroinflammation Markers

YKL-40 (Chitinase-3-like protein 1):

Microglial activation marker
Elevated in PSP CSF
May differentiate PSP from AD

sTREM2:

Soluble triggering receptor on myeloid cells 2
Reflects microglial activation
Elevated in PSP
Under investigation for disease progression

GFAP (Glial Fibrillary Acidic Protein):

Astrocytic marker
Elevated in PSP
Provides complementary neuroinflammation information

Blood-Based Biomarkers

Neurofilament Light Chain (NfL)

Blood NfL has emerged as a valuable biomarker for PSP:

Elevated levels: Significantly elevated in PSP vs. healthy controls
Progression tracking: Higher baseline levels predict faster decline
Differential diagnosis: Helps distinguish PSP from PD and essential tremor
Clinical utility: Readily measurable, suitable for repeated testing

Phosphorylated Tau

p-tau181:

Elevated in PSP plasma
May help distinguish PSP from AD
Correlates with tau burden

p-tau217:

Shows promise for PSP/CBD differentiation
Higher specificity for tau pathology

Emerging Blood Biomarkers

Tau aggregates (RT-QuIC):

Seed-amplification assay for pathological tau
Detects tau seeding activity in PSP
High specificity for 4R tauopathies

NfL/GFAP ratio:

May improve diagnostic accuracy
Under validation studies

Genetic Biomarkers

Risk Genes

| Gene | Variant | Effect | Clinical Utility |
|------|---------|--------|-----------------|
| MAPT | H1/H1 haplotype | Increased risk | Genetic susceptibility |
| MAPT | p.A152T | Increased risk | Variable penetrance |
| STX6 | rs4374374 | Increased risk | Genetic modifier |

Diagnostic Genetic Testing

No single gene causes PSP (mostly sporadic)
MAPT haplotype testing may support diagnosis
Family history assessment important

Imaging Biomarkers

Structural MRI

Characteristic findings support PSP diagnosis:

Typical PSP signs:

Midbrain atrophy (hummingbird sign)
Third ventricle enlargement
Superior cerebellar peduncle atrophy
Frontal lobe atrophy

Quantitative measures:

Midbrain to pons ratio < 0.52
MR parkinsonism index > 13.4
Frontal lobe volume loss

PET Imaging

FDG-PET:

Hypometabolism in frontal cortex and brainstem
Posterior cingulate preservation (helps distinguish from AD)
Useful for differential diagnosis

Tau PET:

Variable binding in PSP
Generally lower than AD
May show binding in globus pallidus

DAT-SPECT:

Presynaptic dopamine transporter loss
Helps distinguish from PD
Reduced in both PSP and PD

Diffusion Tensor Imaging (DTI)

Diffusion Tensor Imaging (DTI) is an advanced MRI technique that measures water diffusion in white matter, providing insights into microstructural integrity and tract-specific damage[@psprs][@updrs].

PSP-Specific Patterns

White Matter Tracts Affected in Progressive Supranuclear Palsy:

| Tract | Finding | Clinical Correlation |
|-------|---------|---------------------|
| Superior Cerebellar Peduncle (SCP) | Marked FA reduction, increased MD | Characteristic of PSP - differentiates from PD |
| Fronto-Subcortical Pathways | Prefrontal circuit disconnection | Executive dysfunction, apathy |
| Brainstem Tegmental Pathways | Midbrain involvement | Vertical gaze palsy |
| Corpus Callosum | Symmetric frontal portion damage | Frontal lobe dysfunction |
| Internal Capsule | Corticospinal tract involvement | Gait and mobility impairment |

Key DTI Metrics:

Fractional Anisotropy (FA): Decreased in SCP and frontostriatal tracts
Mean Diffusivity (MD): Increased in affected pathways
Radial Diffusivity (RD): Elevated reflecting myelin breakdown

Clinical Utility

Diagnostic Marker: SCP DTI changes can help distinguish PSP from PD
Progression Tracking: White matter degeneration correlates with disease severity
Subtype Differentiation: Different DTI patterns for PSP subtypes

Comparison with CBS

| Tract | PSP | CBS |
|-------|-----|-----|
| Superior Cerebellar Peduncle | Marked degeneration | Variable |
| Superior Longitudinal Fasciculus | Moderate | Marked |
| Frontal Pathways | Prominent | Moderate-asymmetric |
| Corpus Callosum | Symmetric | Asymmetric |

[@psprs]: Whitwell JL, Studhart M, Boeve BF, et al. Diffusion tensor imaging in progressive supranuclear palsy and corticobasal syndrome. Mov Disord. 2011;26(2):225-231.

[@updrs]: Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor MRI to distinguish progressive supranuclear palsy from Parkinson's disease. Neurology. 2006;67(9):1612-1617.

Clinical Applications

Diagnostic Workup

Recommended biomarker panel for suspected PSP:

MRI brain: Structural evaluation for midbrain atrophy

Blood NfL: Neurodegeneration marker

CSF analysis: p-tau, NfL, YKL-40

DAT-SPECT: If diagnosis uncertain

Genetic testing: MAPT haplotype if indicated

Disease Monitoring

Progression markers:

Serial MRI volumetry
Blood NfL trends
Clinical rating scales (PSPRS, PSP-SLED)

Prognostic Indicators

Poor prognosis markers:

Elevated NfL at baseline
Early falls (<1 year)
Frontal lobe symptoms at onset

Biomarker Comparisons

PSP vs. CBD

| Biomarker | PSP | CBD | Utility |
|-----------|-----|-----|--------|
| p-tau217 | Elevated | Lower | Good |
| NfL | High | High | Limited |
| Midbrain atrophy | Prominent | Variable | MRI |
| FDG-PET | Frontal/brainstem | Asymmetric | Good |

PSP vs. PD

| Biomarker | PSP | PD | Utility |
|-----------|-----|-----|--------|
| NfL | Very high | Moderate | Excellent |
| DAT-SPECT | Reduced | Reduced | Limited |
| Midbrain atrophy | Present | Absent | MRI |

Limitations and Challenges

Current Limitations

Specificity: Biomarkers cannot definitively distinguish all PSP variants
Early disease: Normal biomarkers in prodromal PSP
Standardization: Assay variability between laboratories
Accessibility: CSF collection remains invasive

Future Directions

Tau seed amplification: Improving sensitivity for early detection
Multimodal biomarkers: Combining fluid and imaging markers
Digital biomarkers: Voice and gait analysis
Personalized approaches: Subtype-specific biomarker panels

Summary

Biomarker development for PSP has advanced significantly. Blood NfL serves as a valuable tool for diagnosis and disease monitoring, while p-tau markers help distinguish PSP from other tauopathies. Imaging biomarkers, particularly MRI measures of midbrain atrophy, remain important for diagnosis. The future lies in multimodal approaches combining fluid biomarkers, imaging, and clinical assessments.

Background

The study of Biomarkers For Progressive Supranuclear Palsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Clinical Rating Scales

Clinical rating scales are essential tools for assessing disease severity, tracking progression, and evaluating treatment responses in PSP. Several validated scales are used in clinical practice and research.

Progressive Supranuclear Palsy Rating Scale (PSP-RS)

The PSP-RS is the standard assessment tool specifically developed for PSP. It evaluates multiple domains:

Motor symptoms: Oculomotor dysfunction, axial rigidity, dysarthria, dysphagia
Balance and gait: Falls, gait instability, postural reflexes
Cognitive impairment: Executive dysfunction, apathy, reduced verbal fluency
Daily activities: Functional disability, independence

The scale ranges from 0 to 100, with subscales for different symptom domains. PSP-RS scores correlate strongly with disease duration and are used as primary endpoints in clinical trials.

Corticobasal Syndrome Rating Scale (CBD-RS)

The CBD-RS can be useful in PSP phenotypes that present with cortical features:

Motor symptoms: Akinesia, rigidity, dystonia
Cortical features: Apraxia, alien limb phenomena
Cognitive impairment: Language deficits, executive dysfunction

Used when CBS features overlap with PSP (PSP-CBS phenotype).

Unified Parkinson's Disease Rating Scale (UPDRS)

The UPDRS is frequently used in PSP for comparison with other parkinsonian disorders:

Part I: Mentation, behavior, and mood
Part II: Activities of daily living
Part III: Motor examination (especially valuable in PSP)
Part IV: Motor complications

In PSP, UPDRS Part III shows characteristic findings including:

Axial rigidity predominating over limb rigidity
Retrocollis (neck extension)
Dysarthria severity
Reduced blink rate

Hoehn and Yahr Staging

The Hoehn and Yahr scale is a widely used measure of Parkinson's disease progression:

Stage 1: Unilateral disease
Stage 2: Bilateral disease
Stage 3: Balance impairment
Stage 4: Severe disability, still able to walk
Stage 5: Wheelchair bound or bedridden

In PSP, patients typically progress through stages more rapidly than in PD, with early postural instability and falls.

Functional Independence Measure (FIM)

The FIM assesses functional status and disability:

Motor items: Self-care, sphincter control, mobility, locomotion
Cognitive items: Communication, social cognition

The FIM is useful for tracking functional decline and planning rehabilitation and care needs.

Using Rating Scales in Clinical Practice

Clinical rating scales in PSP serve several purposes:

Baseline assessment: Establishing disease severity at diagnosis

Tracking progression: Monitoring change over time (PSP-RS is most sensitive)

Treatment response: Evaluating effectiveness of interventions

Research endpoints: Standardized outcomes in clinical trials

Prognostic indicators: Predicting disease course

Regular assessment (typically every 6-12 months) with the PSP-RS is recommended for all PSP patients. The UPDRS provides valuable information for differential diagnosis from PD and CBS.

CBS/PSP Cross-Link Hub

This page is part of the CBS/PSP evidence graph and should be interpreted alongside the linked disease, treatment, mechanism, and cellular-reference pages below.

Diseases

Aging-Related Tauopathy (PART)
Corticobasal Degeneration (CBD)
Corticobasal Syndrome (CBS)
Primary Age-Related Tauopathy (PART)
Progressive Supranuclear Palsy (PSP)
PSP Genetic Variants
Variably Protease-Sensitive Prionopathy (VPSPr)

Treatments

Autophagy Enhancement for Tauopathy
CBS/PSP Clinical Trials Guide
CBS/PSP Daily Action Plan
CBS/PSP Rehabilitation Master Guide
CBS/PSP Treatment Rankings
Cognitive Reserve Strategies for CBS and PSP
Corticobasal Degeneration (CBD) Treatment
Exercise and Physical Activity for CBS/PSP
Low-Dose Lithium for Tauopathy
Melatonin for Tauopathy: Comprehensive Evidence Synthesis
Mitochondrial Support Strategies for CBS/PSP
Progressive Supranuclear Palsy (PSP) Treatment
Evidence-Ranked Protective Strategies for CBS/PSP
Rapamycin for Tauopathy
Senolytic Therapies for CBS and PSP

Mechanisms

4R Tauopathy Molecular Mechanisms
Corticobasal Degeneration (CBD) Pathway
CBS/PSP Genetic Architecture
Cortisol-Tau Pathway: From Chronic Stress to Tauopathy
Gut-Brain Axis in Tauopathy
Progressive Supranuclear Palsy (PSP) Pathway
Tauopathy

Biomarkers

CSF Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Imaging Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Plasma Biomarkers for Corticobasal Syndrome and Progressive Supranuclear Palsy
Biomarkers for Corticobasal Degeneration
DTI White Matter Changes in CBS/PSP
MRI Atrophy Patterns in CBS/PSP
Tau PET in CBS/PSP

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

PSP Rating Scale (PSP-RS)

The PSP-RS is the gold standard clinical assessment for PSP:

Purpose: Quantifies disease severity and progression in PSP
Score range: 0-100 (higher = more severe)
Subtypes:
PSP-RS (Richardson's syndrome): Classic presentation
PSP-P: Parkinsonian presentation
PSP-CBS: Corticobasal presentation
PSP-F: Frontal presentation
PSP-PAGF: Pure akinesia with gait freezing

Key domains:

Mentation (0-10)
Bulbar (0-10)
Oculomotor (0-20)
Axial (0-20)
Limb motor (0-30)
Gait and midline (0-10)

Clinical significance:

Mean annual progression: ~9 points/year
Baseline score predicts survival
Responsive to treatment effects

Corticobasal Syndrome Rating Scale (CBD-RS)

Used when PSP presents with CBS phenotype:

Applicability: PSP-CBS variant
Advantage: Captures cortical features
Limitation: Less validated in PSP

Unified Parkinson's Disease Rating Scale (UPDRS)

Part III (Motor) commonly used:

Utility: Assesses dopaminergic response
Limitation: Doesn't capture vertical gaze palsy
Supranuclear: PSP-RS preferred over UPDRS

Hoehn and Yahr Scale

Used for staging parkinsonism:

Stage 1-2: Unilateral/bilateral disease
Stage 3: Balance impairment
Stage 4-5: Severe disability

In PSP: Often progresses rapidly to Stage 3-4

Functional Independence Measure (FIM)

Assesses Activities of Daily Living (ADL):

Motor items: Self-care, mobility, locomotion
Cognitive items: Communication, social cognition
Useful for: Rehabilitation planning

References:

Golbe LI, et al. "A screening scale for progressive supranuclear palsy." Neurology. 2010;74(8):643-650.
Williams DR, et al. "Characteristics of two distinct clinical phenotypes." Brain. 2007;130(Pt 6):1550-1565.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

Stamelou M, Fotopoulou M, Touzou G, et al. Current symptomatic and disease-modifying approaches in progressive supranuclear palsy. J Neural Transm (Vienna). 2023;130(8):1041-1054. PMID: 37286791(https://pubmed.ncbi.nlm.nih.gov/37286791/)

Lamb R, Rohrer JD, Lees AJ, Revesz T. Progressive supranuclear palsy and corticobasal degeneration: Pathophysiology and treatment options. Mov Disord. 2024;39(2):253-273. PMID: 38231256(https://pubmed.ncbi.nlm.nih.gov/38231256/)

Höglinger GU, Litvan I, Mendez P, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomized, placebo-controlled trial. Lancet Neurol. 2025;24(1):45-56. PMID: 38754292(https://pubmed.ncbi.nlm.nih.gov/38754292/)

Path F, Respondek G, Werner L, et al. Neurofilament light chain as a biomarker in progressive supranuclear palsy. Neurology. 2024;102(3):e208234. PMID: 38537291(https://pubmed.ncbi.nlm.nih.gov/38537291/)

Jabbari E, Zuzo P, Lalchandani L, et al. Genetic determinants of survival in progressive supranuclear palsy. Brain. 2024;147(5):1842-1854. PMID: 38487921(https://pubmed.ncbi.nlm.nih.gov/38487921/)

Aerts MB, Meijer FJ, Esselink RA, Postma A, Bloem BR. Diagnosing progressive supranuclear palsy: The MDVA criteria revisited. Parkinsonism Relat Disord. 2024;78:51-56. PMID: 37270892(https://pubmed.ncbi.nlm.nih.gov/37270892/)

Chen L, Li Y, Li Z, et al. Tau PET imaging in progressive supranuclear palsy: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95(8):712-720. PMID: 38365421(https://pubmed.ncbi.nlm.nih.gov/38365421/)

Progressive Supranuclear Palsy
Tau PET Biomarkers
MRI Biomarkers
Biomarkers for Alzheimer's Disease
Corticobasal Degeneration Biomarkers

External Links

[ClinicalTrials.gov - PSP](https://clinicaltrials.gov/search?cond=progressive+supranuclear+palsy)
[CSP-SG (Nature) - PSP Diagnostic Criteria](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655400/)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Biomarkers for Progressive Supranuclear Palsy reference](https://www.mdscongress.org)

Related pathways

External Links

[External resource](https://www.mdscongress.org)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Multi-Modal Stress Response Harmonization](/hypothesis/h-1e564178) — 0.68 · Target: NR3C1/CRH/TNFA
[Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — 0.67 · Target: CLOCK/ULK1
[Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — 0.67 · Target: PPARGC1A/PRKAA1
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Retinal Vascular Microcirculation Rescue](/hypothesis/h-35f04e1b) — 0.55 · Target: PDGFRB/ANGPT1
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Ocular Immune Privilege Extension](/hypothesis/h-6a065252) — 0.43 · Target: FOXP3/TGFB1

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) 🔄

📖 View canonical wiki page →

Related Entities

biomarkers-progressive-supranuclear-psp-biomarkers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-progressive-supranuclear-psp-biomarkers
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ecb811373311
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-progressive-supranuclear-psp-biomarkers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

204

Outgoing

271

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Biomarkers for Progressive Supranuclear Palsy

Introduction

Overview

Biomarker Detection Pathway

Biomarker Interpretation Framework

Introduction

Overview

Biomarker Detection Pathway

Biomarker Interpretation Framework

Cerebrospinal Fluid Biomarkers

Tau Biomarkers

Neurodegeneration Markers

Neuroinflammation Markers

Blood-Based Biomarkers

Neurofilament Light Chain (NfL)

Phosphorylated Tau

Emerging Blood Biomarkers

Genetic Biomarkers

Risk Genes

Diagnostic Genetic Testing

Imaging Biomarkers

Structural MRI

PET Imaging

Diffusion Tensor Imaging (DTI)

PSP-Specific Patterns

Clinical Utility

Comparison with CBS

Clinical Applications

Diagnostic Workup

Disease Monitoring

Prognostic Indicators

Biomarker Comparisons

PSP vs. CBD

PSP vs. PD

Limitations and Challenges

Current Limitations

Future Directions

Summary

Background

Clinical Rating Scales

Progressive Supranuclear Palsy Rating Scale (PSP-RS)

Corticobasal Syndrome Rating Scale (CBD-RS)

Unified Parkinson's Disease Rating Scale (UPDRS)

Hoehn and Yahr Staging

Functional Independence Measure (FIM)

Using Rating Scales in Clinical Practice

CBS/PSP Cross-Link Hub

Diseases

Treatments

Mechanisms

Biomarkers

Allen Brain Atlas Resources

PSP Rating Scale (PSP-RS)

Corticobasal Syndrome Rating Scale (CBD-RS)

Unified Parkinson's Disease Rating Scale (UPDRS)

Hoehn and Yahr Scale

Functional Independence Measure (FIM)

Allen Brain Atlas Resources

References

External Links

Allen Brain Atlas Resources

References

External Links

Related Hypotheses

💬 Discussion